Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.

Anita CsizmarikNikolett NagyDávid KeresztesMelinda VáradiThilo BrachtBarbara SitekKathrin E Witzke Martin Puhr Ilona TornyiJózsef LázárLászló TakácsGero KramerSabina SevcencoAgnieszka Maj-HesBoris HadaschikPéter NyirádyTibor Szarvas

Published in: Prostate cancer and prostatic diseases (2023)

Our analysis identified baseline FSCN1 serum levels to be independently associated with poor survival of Abi-treated, but not Doc-treated mCRPC patients, suggesting a therapy specific prognostic value for FSCN1.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors